nach oben

Die Diabetologie

Erschienen in:

29.06.2022 | Im Fokus

Diabetes mellitus 2022 – Was ist neu?

verfasst von: Univ.-Prof. Dr. med. Werner A. Scherbaum

Erschienen in: Die Diabetologie | Ausgabe 5/2022

Einloggen, um Zugang zu erhalten

Auszug

Im Folgenden sollen die aus Sicht des Autors wichtigsten neuen Erkenntnisse zu den beim Diabetes Update 2022 vorgestellten und in diesem Heft nicht als Artikel erscheinenden Themen kurz beschrieben werden. Bezüglich der Originaltexte und Kommentare der Referenten wird auf das Original verwiesen [1]. …

Hamann A, Kleinwechter H, Martin S, Stumvoll M (Hrsg) (2022) Update Diabetologie. Seminarunterlagen Diabetes Update 2022 – 17. Diabetologie-Update-Seminar, Mainz

Herold KC et al (2019) An anti-CD3 antibody, tplizumab, in relatives at high risk for type 1. N Engl J Med 381:603–613PubMedPubMedCentralCrossRef

Sims EK, Bundy BN, Stier K et al (2021) Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. Sci Transl Med 13(583):eabc8980PubMedPubMedCentralCrossRef

Fang Z, Liu M, Tao J et al (2022) Efficacy and safety of closed-loop insulin delivery versus sensor-augmented pump in the treatment of adults with type 1 diabetes: a systematic review and meta-analysis of randomized-controlled trials. J Endocrinol Invest 45(3):471–481PubMedCrossRef

Forlenza GP et al (2022) Glycemic outcomes of children 2–6 years of age with type 1 diabetes during the MiniMed™ 670G system trial. Pediatr Diabetes. https://doi.org/10.1111/pedi.13312CrossRefPubMed

Forlenza GP, Buckingham BA, Brown SA et al (2021) First outpatient evaluation of a tubeless automated insulin delivery system with customizable glucose targets in children and adults with type 1 diabetes. Diabetes Technol Ther 23:410–424PubMedPubMedCentralCrossRef

Holt RIG, DeVries JH, Hess-Frischl A et al (2021) The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association fort he Study of Diabetes (EASD). Diabetologia 64:2609–2652PubMedPubMedCentralCrossRef

Schlüter S, Freckmann G, Heinemann L et al (2021) Evaluation of the SPECTRUM training programme for real-time continuous glucose monitoring. A real-world multicentre prospective study in 120 adults with type 1 diabetes. Diabet Med 38(2):e14467PubMedCrossRef

Riddle MC, Cefalu WT, Evans PH et al (2021) Consensus Report: definition and interpretation of remission in type 2 diabetes. Diabetes Care 44(10):2438–3444CrossRef

10.

Gough SM, Casella A, Ortega KH et al (2021) Neuroprotection by the ketogenic diet: evidence and controversies. Front Nutr 8:782657PubMedPubMedCentralCrossRef

11.

Yurista SR, Chong CR, Badimon JJ et al (2021) Therapeutic potential of ketone bodies for patients with cardiovascular disease: JACC State-Of-The-Art Review. J Am Coll Cardiol 77(13):1660–1669PubMedCrossRef

12.

Pietschner R, Kolwelter J, Bosch A et al (2021) Effect of empagliflozine on ketone bodies in patients with stable chronic heart failure. Cardiovasc Diabetol 20(1):219PubMedPubMedCentralCrossRef

13.

Hirschberger S, Strauß G, Effinger D et al (2021) Very-low carbohydrate diet enhances human T cell immunity through immunometabolic reprogramming. EMBO Mol Med 13(8):e14323PubMedPubMedCentralCrossRef

14.

Johannesen CDL, Mortensen MBMB, Lansted A et al (2021) Apolipoprotein B and Non-HDL cholesterol better reflect rsidual risk thaqn LDL cholesterol in Statin-treated in patients with type 2 diabetes: a meta-analysis. J Am Coll Cardiol 77:1439–1450PubMedCrossRef

15.

McDonagh TA, Metra M, Adamo M et al (2021) 2021 EDS Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42:3599–3726PubMedCrossRef

16.

Anker SD, Butler J, Filippatos G et al (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385:1451–1461PubMedCrossRef

17.

McGuire DK, Shih WJ, Cosentino F et al (2021) Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol 6(2):148–158PubMedCrossRef

18.

Bergstrom G, Persson M, Adiels M et al (2021) Prevalence of subclinincal coronary artery atherosclerosis in the general population. Circulation 144:916–929PubMedPubMedCentralCrossRef

19.

Reynolds HR, Shaw LJ, Min JK et al (2021) Outcomes in the ISCHEMIA trial based on coronary artery disease and ischemia severity. Circulation 144(13):1024–1038PubMedCrossRef

20.

Salah HM, Al’Aref SJ, Khan MS et al (2021) Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes—Systematic review and meta-analysis of randomised placebo-conzrolled trials. Am Heart J 232:10–22PubMedCrossRef

21.

Chertow GM, Vart P, Jongs N et al (2021) Effects of dapagliflozin in stage 4 chronic kidney disease. J Am Soc Nephrol 32:2352–2361PubMedCrossRef

22.

McMurray JJV, Wheeler DC, Stefansson BV et al (2021) Effect of dapagliflozin on clinical outcomes in patients with chronic kdney disease. Circulation 143:438–448PubMedCrossRef

23.

Wheeler DC, Toto RD, Stevansson BV et al (2021) A pre-specified analysis oft he DAPA-CKD trial demonstrates the effects of dapagliflocin on major adverse kidney events in pathients with OgA nephropathy. Kidney Int 100:215–224PubMedCrossRef

24.

Wheeler DC, Jongs N, Stefansson BV et al (2021) Safety and efficacy of dapaglifocin in pstients with focal segmental glomerulosclerosis: A prespecified analysis oft he DAPA-CKD trial. Nephrol Dial Transplant. https://doi.org/10.1093/ndt/gfab335CrossRefPubMedPubMedCentral

25.

Ji Q, Ji L, Zhao J et al (2021) Effect of empagliflozin on cardiorenal outcomes and mortality according to body mass index: a subgroup analysis of the EMPA-REG OUTCOME trial with a focus on asia. Diabetes Obes Metab 23:1886–1891PubMedPubMedCentralCrossRef

26.

Jardine M, Zhou Z, Heerspink HJL et al (2021) Kidney, cardiovascular, and safety outcomes of canagliflozin according to baseline albuminuria: a CREDENCE secondary analysis. Clin J Am Soc Nephrol 16:384–395PubMedPubMedCentralCrossRef

27.

Agarwal R, Anker SD, Filippatos G et al (2021) Effects of Canagliflozin versus fineronone on cardiorenal outcomes: exploratory post-hoc analyses from FIDELIO-CKD compared to reported CREDENCE results. Nephrol Dial Transplant. https://doi.org/10.1093/ndt/gfab336CrossRefPubMedPubMedCentral

28.

Chow CK, Atkins ER, Hillis GS et al (2021) Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial. Lancet 398:1043–1052PubMedCrossRef

29.

Neal B, Wu Y, Feng X et al (2021) Effect of salt sunstitution on cardiovascular events and death. N Engl J Mae 385:1067–1077CrossRef

30.

Amarenco P, Kim JS, Labreuche J et al (2020) A comparison of two LDL cholesterol targets after ischaemic stroke. N Engl J Med 382(1):9–19PubMedCrossRef

31.

Bosch J, Lonn EM, Dagenais GR et al (2021) Antihypertensives and statin therapy for primary stroke prevention: a secondary analysis of the HOPE‑3 trial. Stroke 52(8):2494–2501PubMedCrossRef

32.

Liampas A, Rekatsina M, Vadalouca A et al (2021) Pharmacological management of painful peripheral neuropathies. A systematic review. Pain Ther 10(1):55–68PubMedCrossRef

33.

Price R, Smith D, Franklin G et al (2022) Oral and topical treatment of painful diabetic polyneuropathy: Practice Guideline Update Summary: Report oft he AAN Guideline Subcommittee. Neurology 98(1):31–43PubMedCrossRef

34.

Bahron RJ, Gajewski B, Pasnoor M et al (2021) Patient assisted intervention for neuropathy: a comparison of treatment in real life situations (PAIN-CONTRoLS): Bayesian adaptive comparative effectiveness randomized trial. JAMA Neurol 78(1):68–76CrossRef

35.

Vas P, Rayman G, Dhatariya K et al (2020) Effectiveness of interventions to enhance healing of chronic foot ulcers in diabetes: a systematic review. Diabetes Metab Res Rev 36(S1):e3284PubMedCrossRef

36.

Tettelbach W, Cazzell S, Reyzelman AM (2019) A confirmatory study on the efficacy of dehydrated human amnion/choronic membrane dHACM allograft in the management of diabetic foot ulcers: A prospective, multicentre, randomised, controlled study of 110 patients from 14 wound clinics. Int Wound J 16(1):19–29PubMedCrossRef

37.

Game F, Gray K, Davis D et al (2021) The effectiveness of a new dried human amnion derived membrane in addition to standard care in treating diabetic foot ulcers: A patient and asessor blind, randomised controlled pilot study. Int Wound J 18(5):692–700PubMedPubMedCentralCrossRef

38.

Seidel D, Storck M, Lawall H et al (2020) Negative pressure wound therapy comparen with standard moist wound care on diabetic foot ulcers in real-life clinical practice: results oft he German DiaFu-RCT. BMJ Open 10(3):e26345PubMedPubMedCentralCrossRef

39.

Khneizer G, Rizvi S, Gawrieh S (2021) Non-alcoholic fatty liver disease and diabetes mellitus. Adv Exp Biol 1307:417–440CrossRef

40.

Ajmera V, Loomba R (2021) Imaging biomarkers of NAFLD, NASH, anf fibrosis. Mol Metab 50:101167PubMedPubMedCentralCrossRef

41.

Lim GEH, Tang A, Ng CH et al (2021) An observational data meta-analysis oft he differences in the prevalence and risk factors between MAFLD vs NAFLD. Clin Gastroenterol Hepatol. https://doi.org/10.1016/jgh.2021.11.038. Online ahead of printCrossRefPubMed

42.

Wu J, He H, Zhang Q et al (2021) Fasting blood glucose was linearly associated with colorectal cancer risk in the population without self-reported diabetes melllitus history. Medicine 100(34):e26974PubMedPubMedCentralCrossRef

43.

Agha OQ, Alsyid M, Brown MD (2021) Bowel preparation in diabetic patients undergoing colonoscopy. Ann Gastroenterol 34(3):310–315PubMedPubMedCentral

44.

Petrov MS, Basina M (2021) Diagnosis of endocrine Disease: Diagnosing and classifying diabetes in diseases oft he exocrine pancreas. Eur J Endocrinol 184(4):R151–R163PubMedCrossRef

45.

Koromani F, Ghatan S, van Hoek M et al (2021) Type 2 diabetes mellitus and vertebral fracture risk. Curr Osteoporos Rep 19(1):50–57PubMedPubMedCentralCrossRef

46.

Sihota P, Yadav RN, Dhaliwal R et al (2021) Investigation of mechanical, material, and compositional determinants of human trabecular bone quality in type 2 diabetes. J Clin Endocrinol Metab 106:e2271–e2289PubMedCrossRef

47.

Broadwell A et al (2021) Senosumab safety and efficacy among participants in the FREEDOM Extension and treatment of primary Study with mild to moderate chronic kidney disease. J Clin Endocrinol Metab 106(2):397–409PubMedCrossRef

48.

Cohen JB, Cohen DL, Herman DS et al (2021) Testing für primary Aldosteronism and mineralocorticoid receptor antagonist use among U.S. veterans: a retrospective cohort study. Ann Intern Med 174:289–297PubMedCrossRef

49.

Liu YY, King J, Koline GA et al (2021) Outcomes of a specialized clinic on rates of investigation and treatment ofprimary aldosteronism. JAMA Surg 156:541–549PubMedCrossRef

50.

Beumer J, Puschhof J, Bauza-Martinez J et al (2020) High-resolution mRNA and secretome atlas of human enteroendocrine cells. Cell 181(e1219):1291–1306PubMedCrossRef

51.

Baggio LL, Drucker D (2021) Glucagon-like peptide‑1 receptor co-agonists for treating metabolic disease. Mol Metab 46:101090. https://doi.org/10.1016/j.molmet.2020.101090CrossRefPubMed

52.

Le Roux CW, Aylwin SJ, Batterham RL et al (2006) Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 243:108–114PubMedPubMedCentralCrossRef

53.

Del Prato S, Kahn SE, Pavo I et al (2021) Tirzapatide versus insulin glargine in type‑2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet 398:1811–1874PubMedCrossRef

54.

Nahra R, Wang T, Gadde KM et al (2021) Effects of cotadutide on metabolic and hepatic parameters in adults with overweight and obesity and type 2 diabetes: a 54-week randomized phase 2b study. Diabetes Care 44:1433–1442PubMedPubMedCentralCrossRef

55.

Lau DCW, Erichsen L, Francisco AM et al (2021) Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet 398(10317):2160–2172PubMedCrossRef

Titel: Diabetes mellitus 2022 – Was ist neu?
verfasst von: Univ.-Prof. Dr. med. Werner A. Scherbaum
Publikationsdatum: 29.06.2022
Verlag: Springer Medizin
Erschienen in: Die Diabetologie / Ausgabe 5/2022
Print ISSN: 2731-7447
Elektronische ISSN: 2731-7455
DOI: https://doi.org/10.1007/s11428-022-00924-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Diabetes mellitus 2022 – Was ist neu?

Auszug

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2022

Diabetes und Schwangerschaft – Update 2022

Vergleich schwerwiegender kardiovaskulärer Ereignisse, schwerer Hypoglykämien und Gesamtmortalität zwischen pankreoprivem Diabetes mellitus und Typ-2-Diabetes

Diabetes & Psyche: Behandlung durch ein multidisziplinären Team von Vorteil

Gliflozine bei Typ‑2‑Diabetes und Fettlebererkrankung

Update Typ-2-Diabetes: Neues zur Diagnostik und Therapie

Adipositas und Ernährung

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin